These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 16448441)

  • 61. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration.
    Seyhan A; Ata B; Sidal B; Urman B
    Obstet Gynecol; 2008 Feb; 111(2 Pt 2):526-8. PubMed ID: 18239009
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report.
    Ito H; Nishimura T; Abe H; Oka F; Miura T; Uchikoba T; Oaki Y
    Hinyokika Kiyo; 2000 Jul; 46(7):499-503. PubMed ID: 10965460
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Triptorelin embonate: a 6-month formulation for prostate cancer.
    Whelan P
    Expert Opin Pharmacother; 2010 Dec; 11(17):2929-32. PubMed ID: 20969451
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.
    Shioi K; Sakai N; Yoshida M; Nakamura M
    Hinyokika Kiyo; 2005 Mar; 51(3):211-4. PubMed ID: 15852680
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
    Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
    Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
    Uphoff J; Woziwodzki J; Schattka SO; Kollias A
    Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hormonal treatment in prostate cancer.
    Zbranca E; Preda C
    Endocrinologie; 1991; 29(1-2):91-7. PubMed ID: 1803495
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
    Miller K
    MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
    [No Abstract]   [Full Text] [Related]  

  • 72. 'Clandestine' prostate cancer haunts.
    Chapman B
    CAP Today; 1996 Feb; 10(2):1, 34-6, 38 passim. PubMed ID: 10160261
    [No Abstract]   [Full Text] [Related]  

  • 73. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Implantable LHRH agonist for treatment of prostate cancer.
    Lajiness MJ
    Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
    [No Abstract]   [Full Text] [Related]  

  • 75. Effect of luteinizing hormone-releasing hormone agonists on behavior in a patient with dementia.
    Beversdorf DQ; Tomasi MJ
    J Clin Psychopharmacol; 2009 Feb; 29(1):101-2. PubMed ID: 19142125
    [No Abstract]   [Full Text] [Related]  

  • 76. Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.
    Tanios G; Mungo NA; Kapila A; Bajaj K
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710301
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion.
    Patel V; Castell FA; Akinwunmi J; Francis I; Chandrasekharan L; Malhotra R
    Orbit; 2010 Aug; 29(4):213-5. PubMed ID: 20812840
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
    Debruyne F; Bhat G; Garnick MB
    Future Oncol; 2006 Dec; 2(6):677-96. PubMed ID: 17155895
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pure red cell aplasia in a prostate cancer patient treated with leuprolide acetate and chlormadinone acetate.
    Kobayashi M; Nukui A; Morita T
    Int J Urol; 2005 Nov; 12(11):1010-1. PubMed ID: 16351663
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rapid androgen cycling as treatment for patients with prostate cancer.
    Feltquate D; Nordquist L; Eicher C; Morris M; Smaletz O; Slovin S; Curley T; Wilton A; Fleisher M; Heller G; Scher HI
    Clin Cancer Res; 2006 Dec; 12(24):7414-21. PubMed ID: 17189414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.